Pharmaceuticals, Biotechnology and Life Sciences
Zealand Pharma has dosed the first out of 64 healthy patients, in a Phase 1 clinical test of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS).
BOSTON & COPENHAGEN, Denmark–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (NASDAQ:ZEAL) today announced a collaboration to discover and…
Zealand Pharma has doesd its first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism, the company said Wednesday.
Copenhagen-based biotechnology company Zealand Pharma focused on peptide-based drugs,has completed a $5 million equity investment in Beta Bionics, a medical technology company developing the iLet bionic pancreas system.
Zealand Pharma has reported positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes.
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
Zealand Pharma has announced a $10 million milestone payment following Sanofi’s announcement of European Commission marketing authorization in Europe for…
Zealand Pharma has on Monday increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a…
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.